Results 1 to 10 of about 11,405 (213)

Cost-effectiveness analysis of toripalimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. [PDF]

Front Public Health
Wu C, Wei T, Ye X, Dong Z, Chen X.
europepmc   +1 more source

Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab. [PDF]

Cancer Diagn Progn
Kuwano A, Yada M, Tanaka K, Hamamoto T, Kurosaka K, Suzuki H, Motomura K.   +6 more
europepmc   +1 more source

Comparative efficacy and safety of first-line treatments for RAS wild-type metastatic colorectal cancer: A systematic review and network meta-analysis. [PDF]

Mol Clin Oncol
Wu S, Wang C, Liu S.
europepmc   +1 more source

Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. [PDF]

ESMO Gastrointest Oncol
Suenaga M, Mashima T, Kawata N, Dan S, Seimiya H, Yamaguchi K.   +5 more
europepmc   +1 more source

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma. [PDF]

Curr Oncol Rep
Wysocki PT, Chmiel P, Jassem J, Kraj L.
europepmc   +1 more source

Balloon-Expandable Versus Self-Expanding Prostheses for Transcatheter Treatment of Patients With Low-Flow, Low-Gradient Aortic Stenosis. [PDF]

J Am Heart Assoc
Ferruzzi GJ, Bellino M, Silverio A, Saia F, Bruno AG, Boragine P, Buono A, De Rosa ML, Cancro FP, Porto I, Crimi G, Calabrò P, Moscarella E, Ielasi A, Montonati C, De Carlo M, Sticchi A, Lanni F, Di Muro FM, Maiellaro F, Calchera IF, Boccuzzi G, Sorropago A, Scudiero F, Attisano T, Citro R, Granata G, De Luca G, Musumeci G, Galasso G, LOW‐TAVR Investigators.   +30 more
europepmc   +1 more source

On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. [PDF]

Cancers (Basel)
Tajiri K, Muraishi N, Ishizaka E, Murayama A, Hayashi Y, Yasuda I.   +5 more
europepmc   +1 more source

Spatial Proximity Between PD-L1(+) Tumor-Associated Macrophages and CD8(+) T Cells Influences Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma. [PDF]

Cancers (Basel)
Nosaka T, Ohtani M, Yamashita J, Murata Y, Akazawa Y, Tanaka T, Takahashi K, Naito T, Imamura Y, Koneri K, Goi T, Nakamoto Y.   +11 more
europepmc   +1 more source

Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma. [PDF]

Liver Cancer
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Nishimura T, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Matsuura T, Ueda Y, Kim SK, Ohama H, Tada F, Nakamura S, Nakamura Y, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Fukunishi S, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Okamura J, Fukumoto T, Hiasa Y, Kudo M, Kumada T, RELPEC Group, HCC 48 Group.   +58 more
europepmc   +1 more source

Bacterial extracellular vesicles indirectly destabilize a human stem cell-derived blood-brain barrier on-chip through pro-inflammatory stimulation of immune cells.

Lab Chip
Widom LP, Torabian P, Trempel MA, McCloskey MC, Michel LV, McGrath JL, Gaborski TR.   +6 more
europepmc   +1 more source